Seegene launches the world’s first fully automated, zero-stop PCR system, CURECA, and real-time diagnostic data platform, STAgora, at ADLM 2025.
 |
| Seegene redefines diagnostics with CURECA, the first fully automated PCR system, and STAgora, a global data analytics platform, debuting at ADLM 2025 in Chicago. Image: Seegene/ CH |
Seoul, South Korea — July 25, 2025:
Seegene Inc., a leading South Korean innovator in molecular diagnostics, has announced a major breakthrough in global laboratory automation with the unveiling of CURECA, the world’s first fully automated, zero-stop PCR testing system, alongside its real-time data platform STAgora, at ADLM 2025 in Chicago.
The technologies signal a paradigm shift in diagnostics, transforming how labs operate by automating every step of PCR testing and enabling real-time epidemiological insight from global data networks.
The CURECA system is the first to automate the entire PCR testing workflow—from sample storage and pretreatment to nucleic acid extraction, amplification, and result analysis—with no manual intervention required. Designed for 24/7 continuous operation, it greatly reduces human error, increases testing efficiency, and improves diagnostic accuracy across high-volume environments.
A key innovation lies in its automated sample preparation module, capable of processing traditionally labor-intensive samples such as stool, sputum, blood, and urine. This overcomes longstanding hurdles in automating diagnostic labs, especially for high-viscosity samples like feces, where manual processing has long been the norm.
CURECA also supports non-PCR diagnostics such as clinical chemistry and immunoassays, expanding its role across the entire diagnostics ecosystem. Its modular design allows laboratories to customize workflows based on their infrastructure and volume needs.
Also launched at ADLM 2025 is STAgora, Seegene’s next-generation statistical platform for real-time diagnostics, data integration and analytics. By aggregating PCR test results from around the world, STAgora provides insights into local infection trends, co-infection rates, hospital-level positivity patterns, and more—supporting precision medicine at both patient and population levels.
Equipped with 40+ clinical analytics tools, STAgora allows physicians to compare individual patient results with regional and national trends, enabling data-driven, context-aware care decisions.
Seegene is using ADLM 2025 to offer early access programs and seek strategic global partnerships to expand CURECA and STAgora deployments. Earlier in 2025, the technologies were previewed at ESCMID Global, generating substantial global interest.
To support growth in North America, Seegene has established U.S.-based operations, including Seegene Technologies and Seegene CURECA, for R&D and manufacturing.
“CURECA and STAgora are not just products—they’re foundational technologies that will set a new global standard for diagnostics,” said Daniel Shin, EVP and Head of Global Sales and Marketing at Seegene. “We’re excited to share these innovations with the world and continue building the future of laboratory medicine.”
Seegene brings more than two decades of PCR technology leadership, having delivered over 340 million COVID-19 tests to more than 100 countries. Its multiplex PCR technology can simultaneously detect 14 pathogens from a single sample, a capability that proved critical during the global pandemic.
While currently in pre-commercialization, the versions of CURECA and STAgora shown at ADLM 2025 demonstrate the company’s commitment to revolutionizing diagnostics.
As laboratory medicine enters a new era of automation, personalization, and global data integration, Seegene’s technologies mark a defining leap forward for diagnostics worldwide.